Michael Mina, MD, PhD, explains LIBERTY trial findings on VYD2311 tolerability alone and given with an mRNA COVID-19 vaccine.

VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Data from LIBERTY can provide important insight into the VYD2311 clinical profile by direct comparison between COVID antibody prophylaxis and COVID vaccine LIBERTY is part of Invivyd’s broader ...

Invivyd, Inc. is a clinical-stage biotech company developing antiviral monoclonal antibodies, led by its investigational COVID-directed candidate VYD2311 for pre-exposure prophylaxis of symptomatic ...

LIBERTY is a Phase 3, randomized, double-blind clinical trial to evaluate the safety, serum virus neutralizing antibody responses, and pharmacokinetics of VYD2311, an mRNA COVID vaccine, and ...

VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the ...